EU/3/15/1484: Orphan designation for the treatment of cystic fibrosis
Table of contents
On 24 April 2015, orphan designation (EU/3/15/1484) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for nitric oxide for the treatment of cystic fibrosis.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2019 on request of the Sponsor.
Treatment of cystic fibrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Biological Consulting Europe Ltd
15 Station Road, Unit 1
Fife KY10 2BL
Tel. +44 (0)1333 730 170
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: